Trial Profile
A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2018
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 24 Sep 2014 Interim results (n=14) published in the Investigational New Drugs
- 19 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 17 Mar 2014 Planned End Date changed from 1 Aug 2012 to 1 Aug 2014, as per ClinicalTrials.gov record.